ES2105442T3 - Analogos de eritropoyetina con sitios adicionales de glicosilacion. - Google Patents
Analogos de eritropoyetina con sitios adicionales de glicosilacion.Info
- Publication number
- ES2105442T3 ES2105442T3 ES94112732T ES94112732T ES2105442T3 ES 2105442 T3 ES2105442 T3 ES 2105442T3 ES 94112732 T ES94112732 T ES 94112732T ES 94112732 T ES94112732 T ES 94112732T ES 2105442 T3 ES2105442 T3 ES 2105442T3
- Authority
- ES
- Spain
- Prior art keywords
- additional
- erythropoyetin
- analogs
- glycosilation sites
- hepo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
SE PRESENTAN ANALOGOS DE LA ERITROPOYETINA QUE TIENEN AL MENOS UNA REGION ADICIONAL PARA LA GLICOSILACION Y UNA REDISPOSICION DE LA MENOS UNA REGION PARA LA GLICOSILACION. LA INVENCION TAMBIEN SE REFIERE A SECUENCIAS DE ADN QUE CODIFICAN DICHOS ANALOGOS DE ERITROPOYETINA Y A PLASMIDOS RECOMBINANTES Y CELULAS HUESPEDES PARA LA EXPRESION DE LOS ANALOGOS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10801693A | 1993-08-17 | 1993-08-17 | |
US108016 | 1993-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2105442T3 true ES2105442T3 (es) | 1997-10-16 |
ES2105442T5 ES2105442T5 (es) | 2005-07-16 |
Family
ID=22319789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94112732T Expired - Lifetime ES2105442T5 (es) | 1993-08-17 | 1994-08-16 | Analogos de eritropoyetina con sitios adicionales de glicosilacion. |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP0640619B2 (es) |
JP (3) | JP2938572B2 (es) |
KR (2) | KR100328769B1 (es) |
CN (1) | CN1057534C (es) |
AT (1) | ATE155796T1 (es) |
AU (1) | AU677097B2 (es) |
CA (1) | CA2147124C (es) |
CZ (3) | CZ291229B6 (es) |
DE (2) | DE10199059I2 (es) |
DK (1) | DK0640619T4 (es) |
ES (1) | ES2105442T5 (es) |
FI (1) | FI117136B (es) |
GR (1) | GR3024815T3 (es) |
HK (1) | HK1001589A1 (es) |
HU (1) | HU220334B (es) |
IL (4) | IL110669A (es) |
LU (1) | LU90850I2 (es) |
LV (1) | LV10972B (es) |
NL (1) | NL300075I2 (es) |
NO (2) | NO323104B1 (es) |
NZ (1) | NZ273134A (es) |
RU (1) | RU2159814C2 (es) |
SI (1) | SI0640619T2 (es) |
SK (1) | SK282003B6 (es) |
UA (1) | UA49793C2 (es) |
WO (1) | WO1995005465A1 (es) |
ZA (1) | ZA946122B (es) |
Families Citing this family (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5989538A (en) * | 1995-02-15 | 1999-11-23 | Amgen Inc. | Mpl ligand analogs |
US5696250A (en) | 1995-02-15 | 1997-12-09 | Amgen Inc. | DNA encoding megakaryocyte growth and development factor analogs |
AU6964196A (en) * | 1995-10-09 | 1997-04-30 | Pharmacia & Upjohn Company | An acceptor polypeptide for an n-acetylgalactosaminyltransferase |
KR100400637B1 (ko) * | 1996-02-06 | 2004-03-10 | 씨제이 주식회사 | 생물학적으로유용한펩타이드 |
DE69724241T2 (de) | 1996-03-14 | 2004-06-09 | Genentech, Inc., South San Francisco | Gdnf-rezeptor und dessen verwendung |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
DK0902085T3 (da) * | 1997-09-01 | 2004-04-05 | Aventis Pharma Gmbh | Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil |
CA2312188C (en) | 1997-12-08 | 2010-06-29 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US6548653B1 (en) | 1998-06-15 | 2003-04-15 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
US7304150B1 (en) | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
ES2283139T5 (es) * | 1998-10-23 | 2018-03-05 | Amgen Inc. | Métodos y composiciones para la prevención y tratamiento de la anemia |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
PT1151102E (pt) * | 1999-02-12 | 2006-07-31 | Amgen Inc | Composicoes de leptina glicosilada e metodos afins |
US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
WO2003048348A2 (en) | 2001-12-07 | 2003-06-12 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
US6831060B2 (en) | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
IL145785A0 (en) * | 1999-05-07 | 2002-07-25 | Genentech Inc | Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
US6555343B1 (en) | 1999-05-07 | 2003-04-29 | Genentech Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
AU2154401A (en) * | 1999-11-12 | 2001-05-30 | Merck Patent Gmbh | Erythropoietin forms with improved properties |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
DK1252192T3 (da) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
SI1274728T1 (sl) * | 2000-04-21 | 2008-08-31 | Amgen Inc | Postopek in sestavki za prepreäśevanje in/ali zdravljenje anemije |
HU230874B1 (hu) * | 2000-05-15 | 2018-11-29 | F. Hoffmann-La Roche Ag | Pegilezett humán eritropoietin-fehérjét tartalmazó, szobahőmérsékleten stabil folyékony gyógyászati készítmények |
US7259146B2 (en) | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
WO2002011753A1 (fr) | 2000-08-04 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Preparations proteiniques a injecter |
AU2001277781A1 (en) | 2000-08-11 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
DE60117919T2 (de) * | 2000-12-11 | 2006-12-14 | Cheil Jedang Corp. | Fusionsprotein mit verbesserter in vivo erythropoietinwirkung |
KR101229995B1 (ko) | 2000-12-11 | 2013-02-06 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
AU3323002A (en) * | 2000-12-20 | 2002-07-01 | Hoffmann La Roche | Erythropoietin conjugates |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
CA2437333A1 (en) | 2001-02-02 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
MXPA03008031A (es) | 2001-03-07 | 2003-12-04 | Merck Patent Gmbh | Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida. |
EP3088412B1 (en) | 2001-03-09 | 2021-05-05 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
US7531358B2 (en) | 2001-04-17 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Method of quantifying surfactant |
DK1383785T3 (da) | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
US6930086B2 (en) * | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
EP1461065A1 (en) | 2001-11-28 | 2004-09-29 | Ortho-McNeil Pharmaceutical, Inc. | Erythropoietin dosing regimen for treating anemia |
KR100467750B1 (ko) * | 2001-11-29 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
AU2002357784B2 (en) | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE10209822A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
WO2003078959A2 (en) | 2002-03-11 | 2003-09-25 | Ortho Mcneil Pharmaceutical, Inc | Methods for shp1 mediated neuroprotection |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
NZ537306A (en) * | 2002-07-01 | 2008-11-28 | Kenneth S Warren Inst Inc | Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier |
WO2004009627A1 (en) * | 2002-07-19 | 2004-01-29 | Cangene Corporation | Pegylated erythropoietic compounds |
DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
JP4489591B2 (ja) | 2002-08-27 | 2010-06-23 | 中外製薬株式会社 | タンパク質溶液製剤の安定化方法 |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7611700B2 (en) | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
DE20321793U1 (de) | 2002-09-11 | 2010-06-02 | Fresenius Kabi Deutschland Gmbh | Hydroxyalkylstärke-Derivate |
US8420789B2 (en) | 2002-09-11 | 2013-04-16 | Chugai Seiyaku Kabushiki Kaisha | Method for removing DNA contaminants from a protein-containing sample |
CN100348618C (zh) | 2002-09-11 | 2007-11-14 | 弗雷泽纽斯卡比德国有限公司 | 生产羟烷基淀粉衍生物的方法 |
AU2003273413A1 (en) | 2002-10-08 | 2004-05-04 | Fresenius Kabi Deutschland Gmbh | Pharmaceutically active oligosaccharide conjugates |
JP2006503091A (ja) * | 2002-10-17 | 2006-01-26 | ファーミング・インテレクチュアル・プロパティー・ビー.ブイ. | タンパク質の修飾 |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
JP4494977B2 (ja) | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質 |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
JP4865539B2 (ja) | 2003-05-09 | 2012-02-01 | クルセル ホランド ベー ヴェー | E1不死化細胞の培養物及び該培養物を培養して該培養物から得られる産物の収量を増加させる方法 |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
MXPA06003234A (es) | 2003-09-29 | 2006-06-08 | Warren Pharmaceuticals Inc | Citosinas protectoras de los tejidos para el tratamiento y prevencion de la sepsis y la formacion de adhesiones. |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
PL2233150T3 (pl) | 2003-12-30 | 2017-06-30 | Bader | Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek |
DE102004063927A1 (de) | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
WO2005092928A1 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
CN100432107C (zh) * | 2005-10-25 | 2008-11-12 | 北京大学 | 具有促红细胞生长因子活性的蛋白质及其用途 |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
WO2007067564A2 (en) | 2005-12-08 | 2007-06-14 | Amgen Inc. | Improved host cells and culture methods |
CA2630811C (en) | 2005-12-08 | 2016-05-31 | Amgen Inc. | Improved production of glycoproteins using manganese |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
WO2007108505A1 (ja) | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
CN101062407A (zh) | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | 促红细胞生成素在预防或治疗视网膜损伤中的用途 |
CA2652578A1 (en) | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Erythropoietin compositions |
EP2498096A1 (en) | 2006-07-21 | 2012-09-12 | Amgen Inc. | Method of detecting and/or measuring hepcidin in a sample |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
CA2661054A1 (en) | 2006-08-22 | 2008-02-28 | Chugai Seiyaku Kabushiki Kaisha | Prophylactic and/or therapeutic agents for peripheral neuropathy |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
CN101337988B (zh) * | 2006-10-31 | 2013-01-09 | 沈阳三生制药有限责任公司 | 一种新的促红细胞生成素类似物 |
US8895303B2 (en) | 2006-11-13 | 2014-11-25 | Charite-Universitatsmedizin Berlin | Method of cell culture and method of treatment comprising a vEPO protein variant |
EP2120998B1 (en) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
AR065613A1 (es) | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
DK2144923T3 (da) | 2007-04-03 | 2013-05-13 | Biogenerix Ag | Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf |
ES2551123T3 (es) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Proceso mejorado para la producción de azúcares de nucleótido |
JP2010534194A (ja) * | 2007-06-15 | 2010-11-04 | チューリッヒ大学 | 神経系障害の新規な処置法 |
CN103113464B (zh) * | 2007-07-02 | 2014-08-20 | 沈阳三生制药有限责任公司 | 天然人促红细胞生成素类似物 |
CN103073631A (zh) * | 2007-07-02 | 2013-05-01 | 沈阳三生制药有限责任公司 | 一种促红细胞生成素类似物 |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
WO2009043049A2 (en) | 2007-09-27 | 2009-04-02 | Amgen Inc. | Pharmaceutical formulations |
EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
EP2070950A1 (en) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
JP5701064B2 (ja) | 2008-01-25 | 2015-04-15 | アムジエン・インコーポレーテツド | フェロポーチン抗体およびその使用方法 |
US9938333B2 (en) | 2008-02-08 | 2018-04-10 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
CN101965200B (zh) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | 缀合的因子ⅷ分子 |
EP2095829A1 (en) | 2008-02-27 | 2009-09-02 | LEK Pharmaceuticals D.D. | Selenium containing modifying agents and conjugates |
US20110137011A1 (en) | 2008-04-21 | 2011-06-09 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
ES2487846T3 (es) | 2008-05-01 | 2014-08-25 | Amgen, Inc. | Anticuerpos anti-hepcindina y métodos de uso |
EP2334699B1 (en) | 2008-09-23 | 2013-09-11 | F. Hoffmann-La Roche AG | Purification of erythropoietin |
BRPI0919403A2 (pt) | 2008-09-26 | 2017-09-26 | Ambrx Inc | polipeptídeos modificados de eritropoetina animal e seus usos |
CA2742871C (en) | 2008-11-13 | 2018-10-23 | Herb Lin | Methods and compositions for regulating iron homeostasis by modulation of bmp-6 |
UA105785C2 (uk) * | 2009-02-19 | 2014-06-25 | Кселлія Фармасьютікалз Апс | Спосіб очищення ліпопептидів |
US20100272816A1 (en) | 2009-04-27 | 2010-10-28 | Wolfgang Rudinger | Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient |
WO2011011674A2 (en) | 2009-07-24 | 2011-01-27 | Dr. Reddy's Laboratories Ltd. | Production of erythropoiesis stimulating protein using metal ions |
WO2011024025A1 (en) * | 2009-08-28 | 2011-03-03 | Avesthagen Limited | An erythropoietin analogue and a method thereof |
US9662271B2 (en) | 2009-10-23 | 2017-05-30 | Amgen Inc. | Vial adapter and system |
WO2011156373A1 (en) | 2010-06-07 | 2011-12-15 | Amgen Inc. | Drug delivery device |
US8193296B2 (en) | 2010-06-30 | 2012-06-05 | Nike, Inc. | Golf balls including crosslinked thermoplastic polyurethane |
US20120115637A1 (en) | 2010-06-30 | 2012-05-10 | Nike, Inc. | Golf Balls Including A Crosslinked Thermoplastic Polyurethane Cover Layer Having Improved Scuff Resistance |
RU2451071C1 (ru) * | 2010-12-10 | 2012-05-20 | Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) | Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к рекомбинантному эритропоэтину человека (варианты) |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
PT2699293T (pt) | 2011-04-20 | 2019-05-21 | Amgen Inc | Aparelho de autoinjeção |
US9089739B2 (en) | 2011-08-23 | 2015-07-28 | Nike, Inc. | Multi-core golf ball having increased initial velocity |
US8979676B2 (en) | 2011-08-23 | 2015-03-17 | Nike, Inc. | Multi-core golf ball having increased initial velocity at high swing speeds relative to low swing speeds |
IL308846A (en) | 2011-10-14 | 2024-01-01 | Amgen Inc | Syringe and assembly method |
KR101443257B1 (ko) * | 2011-10-18 | 2014-09-19 | 주식회사 종근당 | 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법 |
CN102788720B (zh) * | 2012-06-05 | 2016-01-06 | 西北大学 | 一种滤膜辅助分离生物样本中糖蛋白全n-连接糖链及其鉴别方法 |
AU2013348071B2 (en) | 2012-11-21 | 2018-05-24 | Amgen Inc. | Drug delivery device |
CN103864913A (zh) * | 2012-12-18 | 2014-06-18 | 联亚生技开发股份有限公司 | 重组蛋白 |
TWI580452B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法 |
KR102218494B1 (ko) | 2013-03-15 | 2021-02-19 | 인트린식 라이프사이언시스, 엘엘씨 | 항-헵시딘 항체 및 그의 용도 |
WO2014144096A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
ES2853748T3 (es) | 2013-03-22 | 2021-09-17 | Amgen Inc | Inyector y método de montaje |
ES2744837T3 (es) | 2013-10-24 | 2020-02-26 | Amgen Inc | Inyector y procedimiento de ensamblaje |
AU2014340174B2 (en) | 2013-10-24 | 2019-09-12 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
KR101414897B1 (ko) | 2013-11-29 | 2014-07-04 | 씨제이헬스케어 주식회사 | 다베포에틴 알파의 정제 방법 |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
KR102496507B1 (ko) | 2014-05-07 | 2023-02-03 | 암겐 인코포레이티드 | 충격 감소 요소들을 가진 자동 주사기 |
IL297356A (en) | 2014-06-03 | 2022-12-01 | Amgen Inc | Controllable drug delivery system and method of use |
CN107074928B (zh) * | 2014-09-18 | 2021-03-12 | 奥美药业有限公司 | 新型猫促红细胞生成素受体激动剂 |
US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
EP3428284B1 (en) | 2016-03-09 | 2022-05-11 | JCR Pharmaceuticals CO., LTD. | Method for producing mutant human erythropoietin |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
GB2550418A (en) | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
WO2018136398A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
WO2018151890A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
JP6258536B1 (ja) * | 2017-03-03 | 2018-01-10 | 協和発酵キリン株式会社 | ダルベポエチン組成物の製造方法およびダルべポエチン産生細胞の培養方法 |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
FI3600491T3 (fi) | 2017-03-28 | 2023-10-20 | Amgen Inc | Männänvarren ja ruiskukokoonpanon järjestelmä ja menetelmä |
AU2018281334A1 (en) | 2017-06-06 | 2019-12-19 | Kindred Biosciences, Inc. | Erythropoietin and analogs for veterinary use |
CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
MA49461A (fr) | 2017-06-23 | 2020-04-29 | Amgen Inc | Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
JP2020527376A (ja) | 2017-07-21 | 2020-09-10 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD |
MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
CA3079197A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
WO2019094138A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
CN111278487B (zh) | 2017-11-16 | 2022-06-24 | 安进公司 | 用于药物递送装置的门闩锁机构 |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
CN112351804A (zh) | 2018-07-24 | 2021-02-09 | 安进公司 | 用于施用药物的输送装置 |
US20210228815A1 (en) | 2018-07-24 | 2021-07-29 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
CA3103681A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
AR113091A1 (es) | 2018-09-27 | 2020-01-22 | Univ Nacional Del Litoral | Eritropoyetina humana modificada |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
CA3112214A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
CN112689523A (zh) | 2018-10-15 | 2021-04-20 | 安进公司 | 用于药物递送装置的平台组装方法 |
EA202191037A1 (ru) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | Устройство доставки лекарственного средства, имеющее демпферный механизм |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
US20220031953A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial needle retraction |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
JP2022529319A (ja) | 2019-04-24 | 2022-06-21 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2023209074A1 (en) | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4954437A (en) * | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
AU646822B2 (en) * | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
-
1994
- 1994-08-15 CN CN94109128A patent/CN1057534C/zh not_active Expired - Lifetime
- 1994-08-15 IL IL110669A patent/IL110669A/en not_active IP Right Cessation
- 1994-08-15 ZA ZA946122A patent/ZA946122B/xx unknown
- 1994-08-15 IL IL192290A patent/IL192290A0/en unknown
- 1994-08-16 CA CA002147124A patent/CA2147124C/en not_active Expired - Lifetime
- 1994-08-16 HU HU9501435A patent/HU220334B/hu active Protection Beyond IP Right Term
- 1994-08-16 AT AT94112732T patent/ATE155796T1/de active
- 1994-08-16 AU AU76327/94A patent/AU677097B2/en not_active Expired
- 1994-08-16 DK DK94112732T patent/DK0640619T4/da active
- 1994-08-16 ES ES94112732T patent/ES2105442T5/es not_active Expired - Lifetime
- 1994-08-16 SK SK502-95A patent/SK282003B6/sk unknown
- 1994-08-16 JP JP7507153A patent/JP2938572B2/ja not_active Expired - Lifetime
- 1994-08-16 KR KR1019950701453A patent/KR100328769B1/ko not_active IP Right Cessation
- 1994-08-16 WO PCT/US1994/009257 patent/WO1995005465A1/en active IP Right Grant
- 1994-08-16 EP EP94112732A patent/EP0640619B2/en not_active Expired - Lifetime
- 1994-08-16 RU RU95115239/14A patent/RU2159814C2/ru active
- 1994-08-16 CZ CZ1995917A patent/CZ291229B6/cs not_active IP Right Cessation
- 1994-08-16 DE DE2001199059 patent/DE10199059I2/de active Active
- 1994-08-16 NZ NZ273134A patent/NZ273134A/en not_active IP Right Cessation
- 1994-08-16 SI SI9430078T patent/SI0640619T2/xx unknown
- 1994-08-16 UA UA95058432A patent/UA49793C2/uk unknown
- 1994-08-16 DE DE69404401T patent/DE69404401T3/de not_active Expired - Lifetime
-
1995
- 1995-04-12 NO NO19951445A patent/NO323104B1/no not_active IP Right Cessation
- 1995-04-13 FI FI951792A patent/FI117136B/fi not_active IP Right Cessation
- 1995-04-15 KR KR1019957001453A patent/KR960701994A/ko unknown
- 1995-04-17 LV LVP-95-99A patent/LV10972B/en unknown
-
1997
- 1997-09-22 GR GR970402449T patent/GR3024815T3/el unknown
-
1998
- 1998-01-21 HK HK98100522A patent/HK1001589A1/xx not_active IP Right Cessation
- 1998-08-24 JP JP25324498A patent/JP3664590B2/ja not_active Expired - Lifetime
-
2000
- 2000-05-16 IL IL13618800A patent/IL136188A0/xx unknown
- 2000-05-16 IL IL13618900A patent/IL136189A0/xx unknown
-
2001
- 2001-02-06 CZ CZ2001463A patent/CZ291343B6/cs not_active IP Right Cessation
- 2001-02-06 CZ CZ2001462A patent/CZ291342B6/cs not_active IP Right Cessation
- 2001-11-07 LU LU90850C patent/LU90850I2/fr unknown
- 2001-12-06 NL NL300075C patent/NL300075I2/nl unknown
-
2004
- 2004-06-25 JP JP2004188815A patent/JP3664723B2/ja not_active Expired - Lifetime
-
2007
- 2007-06-29 NO NO2007008C patent/NO2007008I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2105442T3 (es) | Analogos de eritropoyetina con sitios adicionales de glicosilacion. | |
DE69414543D1 (de) | Verwendung von Zusammensetzungen zur Schaumregulierung | |
DE69427944D1 (de) | Mischer anordnungen | |
DE58909359D1 (de) | Substituierte Cycloalkyl- bzw. Heterocyclyl-carbon-säureanilide. | |
DE69412984T2 (de) | Schaltregler | |
KR910006808A (ko) | 피드백 제어 시스템 | |
DE59301830D1 (de) | Hochspannungsschaltfeld | |
DE69411531D1 (de) | System zur drahtspannungssteuerung | |
DE59401268D1 (de) | Eliminieren von abtaststörungen | |
DE9310153U1 (de) | Scheren-Verschraubung | |
NO932965D0 (no) | Ir-ugjennomtrengelig taakedannende blanding | |
KR910010219U (ko) | 팩시밀리의 콘트롤판넬 개폐장치 | |
DE9317100U1 (de) | Steuerungstastatur | |
KR940023251U (ko) | 중앙제어 시스템의 키보드 조립장치 | |
ITVR970024U4 (it) | Manopola di comando | |
DE9313521U1 (de) | Mischer | |
KR940019131U (ko) | 샤아프 펜슬의 필심파이프 조절장치 | |
SE8901165D0 (sv) | Styrsystem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 640619 Country of ref document: ES |
|
SPCG | Supplementary protection certificate granted |
Free format text: DARBEPOYETINA ALFA (ARANESP) Spc suppl protection certif: C200100044 Filing date: 20011127 Expiry date: 20160608 Effective date: 20040216 |